Introduction

Hepatoblastoma (HB) is the most common primary hepatic tumour accounting for 50% of malignant hepatic tumours in children (1), with an annual incidence of 1.2–1.5 cases per million population (2,3). There are different histological subtypes with varying prognosis. Of the various molecular pathways of tumourigenesis, Wnt/beta-catenin pathway has gained importance recently. A simple way of identifying derangement in this pathway is by applying immunohistochemical (IHC) marker beta-catenin. There are not many studies comparing the expression of beta-catenin with histological subtypes and survival outcome in HB and results of the existing studies are
Progenitor cells which express CK19 and/or EpCAM (7) play an important role in development of normal liver. HB arises from precursor small cells which at various stages of differentiation give rise to various subtypes thus recapitulating normal development (8,9). Hence, tumour differentiation depends on the stage at which malignant transformation occurs. In addition, CK19 expression has been found to correlate with aggressive behaviour in HB (6) as in hepatocellular carcinoma (7). Hepatic progenitor cells with a proliferative phenotype are associated with expression of EpCAM, which is expressed in 70–80% of HBs (8). Since EpCAM expression is independent of previous cisplatin based chemotherapy, it can be used as a tumour marker and a potential target for immunotherapy (9).

This study aimed to look in detail the morphological subtypes and compare the IHC expression of CK19, beta-catenin and EpCAM with histological subtypes, tumour behaviour, response to chemotherapy and survival. To date, there are no studies that have analysed the IHC expression in pre- and post-chemotherapy specimens of HB in Indian population.

Pathological assessment
For resection specimens, size, appearance (solid/cystic) and presence or absence of tumour necrosis were noted. Histological parameters analysed in both biopsy and resection specimens included histological subtype, mitotic activity/10 high power fields (hpf) with a cut off value of 5/10 hpf to designate tumours into low or high mitotic categories, presence of extramedullary haematopoeisis (EMH) and steatosis within the tumour.

Histologically, tumours were classified into six major subtypes: pure fetal epithelial, mixed embryonal and fetal epithelial, macro trabecular, small cell undifferentiated (SCUD) and mixed epithelial and mesenchymal (MEM) with and without teratoid features (10). A tumour was assigned a category depending on the predominant epithelial subtype (≥60%) exhibited. Tumours with 60:40 ratios of two or more components were classified as mixed subtype. However, for final diagnosis and statistical analysis, tumours were classified as predominantly fetal epithelial (includes pure fetal and predominantly fetal), mixed epithelial (includes predominantly embryonal and mixed fetal and embryonal), macro trabecular, SCUD and MEM with and without teratoid features.

In post-chemotherapy resections percentage of viable tumour was assessed and graded as <25%, 25%–<50% and ≥50%. Effects of chemotherapy and presence of microvascular invasion (MVI) were documented. Surgical resection margin was measured microscopically and categorised as ≤0.5, 0.6–1 and >1 cm.

Immunohistochemistry
IHC staining for CK19, EpCAM and beta catenin were carried out on selected blocks of 37 and 30 cases in the pre- and post-chemotherapy groups respectively, using Ventana Benchmark XT (CK19—clone b170, 1:150 dilution; beta-catenin—clone 17C2, 1:100 dilution; EpCAM—clone VU-1D9, pre-diluted RTU, Novocastra, Leica Biosystems, Melbourne, Australia). For CK19, >5% of tumour cells expressing moderate or strong membranous staining was taken as positive. It was assessed in fetal and embryonal subtypes separately and graded as 5–25%, 26–50% and >50%. Nuclear ± cytoplasmic expression of beta-catenin in >5% cells with moderate/strong staining was taken as positive. Membranous staining for EpCAM was considered as positive and Spizzo’s (11) scoring system was used.
Statistical analysis

Description of data was summarised using frequency along with percentages for categorical variables and mean along with standard deviation for continuous variables using SPSS software Version Stata IC/13. Chi-square/Fisher's exact test was used to compare the association between categorical variables and P value of \( \leq 0.05 \) was considered significant. Overall survival (OS) and event free survival (EFS) were calculated. Event was described as death/metastasis/recurrence. Kaplan-Meir curve was used to depict survival and log rank test was used to compare survival in different groups.

Results

Demographic and clinical details

Mean (range) age of patients at presentation was 2.33±2.47 (0.05–13) years with a male: female ratio of 2.1:1 [37 and 18]. Most common clinical presentation was abdominal mass (38.2%) followed by fever (31%) and abdominal pain (14.6%). Two patients (3.6%) with HB were also found to have horseshoe kidney in two patients, of which one also had medullary sponge kidney and gonadal enlargement with precocious puberty and gastrochisis in one each. Median (range) AFP level at diagnosis was 30,000 (4.32–549,400) IU/mL (n=46). One patient with normal serum AFP level (4.32 IU/mL) was diagnosed to have SCUD subtype. Decrease in serum AFP levels following chemotherapy and surgery was observed in 22/28 (78.6%) patients (Figure 1). Three patients had elevated serum beta-hCG at presentation and two died of disease.

Details about PRETEXT stage were available in 25 patients. Thirteen patients (52%) belonged to PRETEXT-II, 6 (24%) in PRETEXT-III and 3 patients each in PRETEXT-I (12%) and PRETEXT-IV (12%).

Of the 55 tumours, 30 (54.5%) were present in right lobe, 11 (20%) in left lobe and 14 (25.5%) involved both lobes. Of the 37 patients, 30 (81.1%) had a single tumour nodule, while 7/37 (18.9%) had multiple tumour nodules in the liver. Radiologically, average size of the tumour at initial presentation was 10.06±3.12 cm (n=43) and in post chemotherapy resection specimens (grossly) it was 6.70±2.89 cm. This difference in size between the two groups was statistically significant (P\( \leq 0.001 \)) (n=25/33).

Gross details

Of the 33 resected tumours, 28 (84.8%) had solid cut surface and 5 (15.2%) had both solid and cystic appearance. Necrosis was grossly evident in 8 (24.2%) cases. The tumours had a lobulated, firm, tan to grey white or variegated cut surface with haemorrhage, cystic change, hyalinisation and calcification or ossification (Figure 2A,B,C,D).

Microscopic findings (Figure 3A,B,C,D,E,F)

Most common epithelial subtype was fetal in 19/44 (43.2%) and mixed epithelial in 17/31 (54.8%) cases, in pre- and post-chemotherapy groups respectively. SCUD and macro trabecular subtypes were seen in one each.

EMH was noted in 21/44 (47.7%) and 24/33 (72.7%) tumours with erythroid most commonly and megakaryocytes in 3 and 6 tumours in pre- and post-chemotherapy groups respectively. Average number of mitosis/10 hpf was 2 and 1 in fetal and 6 and 11, in embryonal subtypes, in pre- and post-chemotherapy groups respectively. In pre-chemotherapy group, 85.3% and 36% of tumours in fetal and embryonal subtypes had a mitotic count of \( \leq 5/10 \) hpf, respectively. One patient with fetal subtype had a mitotic count of 15/10 hpf and was categorised as 'mitotically active fetal type'. But following chemotherapy, all (100%) fetal subtype tumours had a mitotic count of \( \leq 5/10 \) hpf when compared to embryonal subtype (47%) (P\( \leq 0.001 \)).

Steatosis was seen in 14/44 (31.8%) and 7/33 (21.2%) tumours in pre- and post-chemotherapy groups respectively with all tumours in pre-chemotherapy group, belonging to predominantly fetal subtype (100%) (P=0.03). Osteoid...
was noted in 8/44 (18.2%) and 25/33 (75.8%) tumours in pre- and post-chemotherapy groups respectively. MVI was present in 14/33 (42%) resected tumours and these patients had lower EFS (46.2 months) when compared to those without (72.8 months) (P=0.08). Details of various subtypes of HB are shown in Table 1.

Following chemotherapy, 19/33 (55.6%) patients had ≥50% viable tumour. It was also found that 10/11 (90.9%) cases of MEM subtype and one case with SCUD subtype had ≥50% viable tumour (P=0.07). One tumour had extensive ossification with a few viable islands of normal looking hepatocytes (highlighted by EpCAM), indicating that these islands are actually tumour cells. When percentage of viable tumour was correlated with intensity of expression of EpCAM, 93.9% of cases with intense expression had ≥50% viable tumour (P=0.04).

Chemotherapy induced changes noted were hyalinisation, ossification, recent and old haemorrhage, necrosis, giant cell reaction, squamous differentiation and calcification. Margin could be measured for 30 tumours, of which 22 (73.4%) had a margin clearance of ≤0.5 cm, 4 (13.3%) 0.6–1 cm and 4 (13.3%) with >1 cm clearance. Only 18/22 patients with margin ≤0.5 cm had follow-up data available and 6 patients (33.3%) died of disease. Recurrence was found in 3/55 patients (one MEM and two mixed epithelial subtype) with a margin of ≤0.5 cm in the resected tumour. Distant metastasis was documented in 10/55 (18.2%) patients, most common site being the lung in 5/10 (50%) cases. Other sites of metastasis were omentum, ileum, lymph nodes, mesentery, diaphragm, brain and bones.

Survival data was available for 35/55 patients and 15 (42.9%) died due to disease. It was found that higher number of patients in PRETEXT III (83.3%) and PRETEXT IV (100%) succumbed to the disease compared to those in PRETEXT I and PRETEXT II (P≤0.001) (Figure 4A). Patients with predominantly fetal subtype of tumour had comparatively decreased chance of MVI, recurrence, metastasis and death; however, it was not statistically significant (Figure 4B).

**IHC expression of CK19, beta-catenin and EpCAM**

Staining pattern of various subtypes for CK19, beta-catenin and EpCAM are depicted in (Figure 5A,B,C).

CK19 expression was found in 21.9% and 17.4% in fetal and 54.2% and 72.2% in embryonal subtypes with a significant difference in both pre (P=0.01) and post (P<0.001) chemotherapy groups. In pre-chemotherapy

---

**Figure 2** Gross appearances of HB post-chemotherapy. (A) Variegated yellowish orange to grey white cut surface and with areas of haemorrhage (B) multinodular HB. (C) Extensive ossification (D) ileal metastasis. HB, hepatoblastoma.
Figure 3 Microscopic subtypes of HB. (A) Fetal subtype: shows trabeculae of polygonal cells resembling fetal hepatocytes (H&E, ×200); (B) embryonal subtype: tumour cells with small angulated and hyperchromatic nuclei arranged in pseudo-acinar pattern (arrow) (H&E, ×400); (C) mixed fetal and embryonal subtypes (H&E, ×400); (D) SCUD subtype with sheets of non-cohesive small cells with high nuclear:cytoplasmic ratio (H&E, ×200); (E) MEM: fetal type admixed with islands of osteoid (H&E, ×100); (F) MEM with teratoid subtype: Epithelial component admixed with cartilage, osteoid and smooth muscle with immature mesenchyme in the background (H&E, ×400). MEM, Mixed epithelial and mesenchymal; SCUD, small cell undifferentiated.

Table 1 Various subtypes of HB in the pre- and post-chemotherapy groups

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Pre-chemotherapy; n (%) (n=44)</th>
<th>Post-chemotherapy; n (%) (n=31*)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Predominantly fetal</td>
<td>17 (38.6)</td>
<td>8 (25.8)</td>
</tr>
<tr>
<td>Mixed epithelial</td>
<td>21 (47.7)</td>
<td>11 (35.5)</td>
</tr>
<tr>
<td>MEM</td>
<td>5 (11.4)</td>
<td>11 (35.5)</td>
</tr>
<tr>
<td>SCUD</td>
<td>1 (2.3)</td>
<td>1 (3.2)</td>
</tr>
</tbody>
</table>

* two patients had no viable tumour following chemotherapy. MEM, Mixed epithelial and mesenchymal; SCUD, small cell undifferentiated.
group, CK19 expression was present in >50% of cells in 46.2% of tumours with embryonal subtype, but 85.7% of tumours with fetal subtype showed expression only in <25% of tumour cells (P≤0.04).

Nuclear expression of beta-catenin expression was present in 48.7% and 57.1% of tumours in pre- and post-chemotherapy groups respectively with strong expression in majority of tumours.

EpCAM was expressed in 37/37(100%) and 23/28 (82.1%) tumours in pre- and post-chemotherapy groups, respectively and majority of tumours in both groups, 34/37 (91.9%) and 19/23 (82.6%) respectively showed intense expression. When percentage of viable tumour was correlated with intensity of expression of EpCAM, 93.9% of cases with intense expression had ≥50% viable tumour (P=0.04) (Figure 6). One case with good response
to chemotherapy with predominantly ossified areas and few viable clusters resembling normal hepatocytes on H&E examination were found to be immunopositive for EpCAM.

Comparison of IHC marker expression with tumour behaviour

Patients with embryonal subtype of tumour with CK19 expression had higher incidence of MVI, recurrence, metastasis and death. Increased mortality and adverse outcome was also seen in patients with EpCAM and beta-catenin (nuclear) expression. However, these differences were not statistically significant (Table 2).

Survival analysis

A total of 23 patients with follow up details available were taken for analysis. Overall median (range) survival was 59.5 months (95% CI: 35.7–83.3). At 109 months (9 years) of follow-up, the estimated freedom from metastases was 56.5% (95% CI: 34.5–76.8%) (Figure 7).

Patients with embryonal subtype of tumour with CK19 expression had higher incidence of MVI, recurrence, metastasis, and death. Increased mortality and adverse outcome was also seen in patients with EpCAM and beta-catenin (nuclear) expression. However, these differences were not statistically significant (Table 2).

Table 2. Comparison of expression of CK19, beta-catenin and EpCAM with tumour behaviour

<table>
<thead>
<tr>
<th>Clinico-pathologic variables</th>
<th>CK19 expression</th>
<th>Beta-catenin expression (n=25)</th>
<th>EpCAM expression (n=28)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Fetal subtype (n=23)</td>
<td>Embryonal subtype (n=18)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Absent n (%)</td>
<td>Present n (%)</td>
<td>P value</td>
</tr>
<tr>
<td>MVI</td>
<td>-  8 (42.1) 2 (50) 0.77</td>
<td>1 (20) 5 (39.3) 0.19</td>
<td>4 (44.4) 7 (43.8) 0.64</td>
</tr>
<tr>
<td>Recurrence</td>
<td>-  2 (10.5) 0 (0) 0.49</td>
<td>1 (20) 2 (15.4) 0.73</td>
<td>9 (100) 13 (81.3) 0.36</td>
</tr>
<tr>
<td>Metastasis</td>
<td>-  4 (21) 0 (0) 0.31</td>
<td>5 (100) 7 (53.9) 0.31</td>
<td>7 (77.8) 13 (81.3) 0.60</td>
</tr>
<tr>
<td>Death*</td>
<td>-  4 (26.7) 2 (50) 0.37</td>
<td>3 (75) 7 (58.3) 0.55</td>
<td>4 (66.7) 10 (66.7) 0.68</td>
</tr>
</tbody>
</table>

*, death details were available only for 19 and 16 patients in the fetal and embryonal groups respectively, for CK19 and 21 and 24 patients in the beta-catenin and EpCAM groups respectively; +, positive; −, negative. MVI, microvascular invasion.

Discussion

HB is the most common primary tumour of liver affecting infants and children, with two-third of cases presenting in first 2 years and 90% occurring within 2 years of life as described previously (12). One patient in our study was diagnosed to have HB antenatally, which is a very rare presentation (14).

Serum AFP is the most sensitive marker which is elevated in 90% of HB patients (15) and 97.6% of patients in our study had an elevated AFP level at presentation. Decrease in AFP levels was seen in patients with solitary tumour, and those treated with chemotherapy. Other factors like age at diagnosis ≤2 years, male sex, AFP levels <10,000 IU/mL following chemotherapy, size ≤5 cm, PRETEXT I&II, mitosis ≤2/10 hpf and absent nuclear expression of beta-catenin also had higher EFS rates, though not statistically significant (Table 3).

Kaplan-Meier survival estimates for EFS

There was a significant difference in EFS between patients with solitary tumour when compared to multiple nodules (P=0.001) and <50% viable tumour when compared to ≥50% viable tumour following chemotherapy (P=0.04) (Figure 7B,C). Other factors like age at diagnosis ≤2 years, male sex, AFP levels <10,000 IU/mL following chemotherapy, size ≤5 cm, PRETEXT I&II, mitosis ≤2/10 hpf and absent nuclear expression of beta-catenin also had higher EFS rates, though not statistically significant (Table 3).

Comparison of IHC marker expression with tumour behaviour

Patients with embryonal subtype of tumour with CK19 expression had higher incidence of MVI, recurrence, metastasis, and death. Increased mortality and adverse outcome was also seen in patients with EpCAM and beta-catenin (nuclear) expression. However, these differences were not statistically significant (Table 2).
noted following chemotherapy and surgery in 78.6% of patients (P≤0.001). Elevated beta-hCG is associated with poor prognosis (16) and in this study three patients had elevated levels of beta-hCG, of which two died of disease.

Better EFS was observed for patients in PRETEXT I & II, when compared to PRETEXT III and IV stages as described in other studies (17,18) and higher number of patients in PRETEXT III and IV succumbed to the disease when compared to PRETEXT I&II (P≤0.001).

Mean EFS of patients with multifocal tumour was only 8.2 months when compared to 58.8 months for those with a single tumour (P=0.001), which is similar to other studies (19). There was a significant decrease in tumour size following chemotherapy, indicating the chemosensitive nature of HB. Following chemotherapy, there is a substantial decrease in mitosis in fetal as compared to embryonal subtype (20) and in this study, all (100%) fetal and 47% embryonal tumours had mitosis of ≤5/10 hpf (P≤0.001). Osteoid was noted in 18.2% and 75.8% of tumours in pre- and post-chemotherapy groups respectively. Direct correlation between prognosis and proportion of osteoid has been documented previously (21) and two patients who had extensive ossification had no evidence of recurrence or metastasis. MVI was noted in 14 of 33 (42%) tumours and patients without MVI had EFS of 72.8 months when compared to 46.2 months in patients with MVI (22).

Comparing histological subtypes with adverse events, fetal subtype had a lower incidence of MVI, recurrence, metastasis and death which was similar to other studies (22,23). Patients with <50% of viable tumour following chemotherapy had higher EFS when compared to patients with >50% viable tumour (P=0.04). An interesting finding noted in this study was that majority of tumours with MEM subtype and the one with SCUD subtype had >50% viable tumour, indicating chemoresistance of these subtypes. SCUD pattern, even when present as a minor component, affects prognosis significantly (24) and in this study two cases with focal SCUD areas had MVI and metastasis, while the patient with pure SCUD subtype developed metastasis and succumbed to the disease. However, Gupta et al. (25) and Conran et al. (26) have found no significant association between histological subtype and survival.

When distance of the tumour from resection margin was compared with death, it was found that 33.3% of cases with margin ≤0.5 cm died of disease. In this study, it was also found that these patients had other features of prognostic importance like MVI (4 cases), SCUD (1 case) subtype and lung metastasis (1 case), which can independently predict poorer outcome, irrespective of margin status (27,28).

CK19 expression was found in more number of embryonal (54.2% & 72.2%) subtype in pre- and post-chemotherapy groups respectively, when compared to fetal subtype (21.9% and 17.4%). This comparison was not done in previous studies. SCUD type also showed strong
expression of CK19 and high frequency of expression of CK19 in embryonal and SCUD subtype confirms that it is a marker of embryonic stem cell and histogenesis of HB from embryonic cells (5). In this study, CK19 was found to be a marker of aggressiveness as described in other studies on HB (29) as well in hepatocellular carcinoma (7).

Nuclear expression of beta-catenin was present in 48.7% and 57.1% of tumours in pre- and post-chemotherapy groups respectively, which was similar to the study by Gupta et al. (25). A recent study (30) has documented weak beta-catenin expression in clear cell and hepatocellular carcinoma-like types of HB and strong expression in all pre-treated HBs. However, in this study, there was no significant difference between histological subtypes and beta-catenin expression. Results of comparison of beta-catenin expression with outcome are highly variable. In our study, patients with nuclear expression of beta-catenin were found to have decreased EFS (45.1 months), when compared to those without (66.7 months). Though Gupta et al. (25) found a relatively better prognosis with nuclear beta-catenin expression studies from Europe (31) and United States (20) have found no prognostic difference. These differences in expression of beta catenin could be explained based on the different genetic and environmental factors and also the multiple oncogenic pathways involving beta-catenin.

EpCAM expression was seen in 100% and 82.1% of tumours in pre- and post-chemotherapy groups respectively, which is similar to previous studies (4,32). Majority (>90%) of tumours with strong expression of EpCAM had ≥50% viable tumour following chemotherapy (P=0.04). To our knowledge, there is no data available in literature which correlates EpCAM expression and viability of tumour.

<table>
<thead>
<tr>
<th>Clinicopathologic variables</th>
<th>Categorization</th>
<th>Mean survival (in months)</th>
<th>No. of events</th>
<th>95% confidence interval</th>
<th>P value (≤0.05)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at diagnosis</td>
<td>≤2 years</td>
<td>58.6</td>
<td>8</td>
<td>33.7–83.6</td>
<td>0.94</td>
</tr>
<tr>
<td></td>
<td>&gt;2 years</td>
<td>23</td>
<td>1</td>
<td>7.9–38.1</td>
<td>0.09</td>
</tr>
<tr>
<td>Sex</td>
<td>Males</td>
<td>64.3</td>
<td>7</td>
<td>39.2–89.4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Females</td>
<td>7.5</td>
<td>2</td>
<td>4.2–10.7</td>
<td></td>
</tr>
<tr>
<td>AFP Post chemo</td>
<td>&lt;10,000 IU/mL</td>
<td>50.9</td>
<td>5</td>
<td>30.8–71.1</td>
<td>0.34</td>
</tr>
<tr>
<td></td>
<td>&gt;10,000 IU/mL</td>
<td>47.6</td>
<td>3</td>
<td>2.9–92.2</td>
<td></td>
</tr>
<tr>
<td>No. of lesions</td>
<td>Solitary</td>
<td>58.8</td>
<td>5</td>
<td>37.9–79.7</td>
<td>0.001*</td>
</tr>
<tr>
<td></td>
<td>Multiple</td>
<td>8.2</td>
<td>4</td>
<td>3.3–13.1</td>
<td></td>
</tr>
<tr>
<td>Tumour size</td>
<td>≤5 cm</td>
<td>72.5</td>
<td>2</td>
<td>32–113</td>
<td>0.67</td>
</tr>
<tr>
<td></td>
<td>&gt;5 cm</td>
<td>50.3</td>
<td>3</td>
<td>22.3–78.3</td>
<td></td>
</tr>
<tr>
<td>PRETEXT</td>
<td>I&amp;II</td>
<td>63.9</td>
<td>3</td>
<td>41.2–86.6</td>
<td>0.23</td>
</tr>
<tr>
<td></td>
<td>III&amp;IV</td>
<td>43.8</td>
<td>2</td>
<td>9.4–97</td>
<td></td>
</tr>
<tr>
<td>MVI</td>
<td>Absent</td>
<td>72.8</td>
<td>1</td>
<td>55.4–90.3</td>
<td>0.08</td>
</tr>
<tr>
<td></td>
<td>Present</td>
<td>46.2</td>
<td>7</td>
<td>18.4–74</td>
<td></td>
</tr>
<tr>
<td>Mitotic count</td>
<td>≤2/10 hpf</td>
<td>88.6</td>
<td>1</td>
<td>54.4–122.7</td>
<td>0.10</td>
</tr>
<tr>
<td></td>
<td>&gt;2/10 hpf</td>
<td>28.9</td>
<td>6</td>
<td>4.1–53.7</td>
<td></td>
</tr>
<tr>
<td>Viable tumour</td>
<td>&lt;50%</td>
<td>109.9</td>
<td>0</td>
<td>109.9–109.9</td>
<td>0.04*</td>
</tr>
<tr>
<td></td>
<td>≥50%</td>
<td>39.3</td>
<td>8</td>
<td>18.4–60.2</td>
<td></td>
</tr>
<tr>
<td>Beta-catenin nuclear expression</td>
<td>Absent</td>
<td>67</td>
<td>2</td>
<td>22–111.4</td>
<td>0.67</td>
</tr>
<tr>
<td></td>
<td>Present</td>
<td>45.1</td>
<td>5</td>
<td>18.1–71.4</td>
<td></td>
</tr>
</tbody>
</table>

*, indicates statistically significant differences; AFP, alpha-fetoprotein; PRETEXT, pre-treatment extent of disease; MVI, microvascular invasion.
Maturation of tumour cells is known to occur following chemotherapy and EpCAM expression would be useful in identifying these tumour clusters. In addition identifying EpCAM positive tumours may aid in targeted therapy with monoclonal antibodies improving the survival of those patients who are resistant to conventional chemotherapy (9).

Recurrence of tumour was found in 3 of 55 (5.5%) cases in our study and all three had persistent increase in AFP levels following chemotherapy/surgery. This can be used as a useful adjunct in monitoring patients for metastasis, recurrence and/or relapse (33,34). Distant metastasis was seen in 10 (18.2%) cases of which lung was the most common site, seen in 5 cases, as described previously (35). OS for patients who presented with lung metastasis was found to be lower (28.4 months) when compared to those without (75.9 months) (36,37).

Details about death was available for 35 of 55 cases, of which 15 (42.9%) died of disease. This was higher than North Indian (25) and German (38) studies, which documented only 21% and 23% deaths respectively. This may be due to more number of patients presenting at higher disease stage in our study. However, stage of disease at presentation was not mentioned in the previous studies.

Overall median survival of our patients was 70.7 months, and 5-year OS was 60% which is similar to other studies who have reported a 5-year OS of 63% (39) and 58.7% (40). Mean EFS in our study was 59.5 months and at 9 years of follow-up, estimated freedom from metastases was 56.5%, when compared to 77% metastasis free survival at 2 years of follow-up in a study by Wang et al. (41).

Although stage of tumour at diagnosis remains the key factor in determining prognosis, (26,42,43) various clinical and histological factors have also been implicated in prognostication (6,25,41,44-46). In this study, multifocality and percentage of viable tumour ≥50% were significant factors when EFS was compared. Other factors like age at diagnosis ≤2 years, male sex, AFP level <10,000 IU/mL following chemotherapy, size ≤5 cm, PRETEXT I&II, mitosis ≤2/10 hpf and absent nuclear expression of beta-catenin were also associated with higher EFS.

In conclusion, this study has looked at the histopathological subtypes of HB and compared the IHC expression of CK19, Beta-catenin and EpCAM with survival in 55 cases, diagnosed over a period of 16 years. A larger multicentre collaborative study is required for proper validation of results and also to identify potential biomarkers which can be useful in targeted therapy for HB.

Acknowledgements

We thank Mrs. Mahasampath Gowri. S, Department of Biostatistics, for her assistance in statistical analysis. This study was funded by the Fluid Research Fund, Christian Medical College, Vellore, India.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical statement: This study was approved by the Institutional Review Board, Christian Medical College, Vellore, India (IRB Min No. 8985). As this study did not involve human subjects directly and used the stored formalin fixed paraffin embedded tissue blocks, a waiver of consent was obtained.

References


Cite this article as: Kiruthiga KG, Ramakrishna B, Saha S, Sen S. Histological and immunohistochemical study of hepatoblastoma: correlation with tumour behaviour and survival. J Gastrointest Oncol 2018;9(2):326-337. doi: 10.21037/jgo.2018.01.08